Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
Status: | Completed |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - 40 |
Updated: | 4/13/2015 |
Start Date: | February 2015 |
End Date: | May 2015 |
Contact: | Gilead Study Team |
Email: | 372-1666@gilead.com |
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Subjects
This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with
dofetilide-induced QTc prolongation.
dofetilide-induced QTc prolongation.
Inclusion Criteria:
- Must, in the opinion of the investigator, be in good health based upon medical
history and physical examination, including vital signs
- Have a calculated body mass index (BMI) from 18 to 30 kg/m^2, inclusive, at study
screening
- Have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that
are considered clinically insignificant and which do not interfere with the ability
to interpret the QT interval in the opinion of the investigator in consultation with
the medical monitor
Exclusion Criteria:
- History of meningitis or encephalitis, epilepsy, seizures (known or suspected),
migraines, tremors, myoclonic jerks, sleep disorder, anxiety, syncope, head injuries,
or a family history of seizures
- Have any serious or active medical or psychiatric illness (including depression)
which, in the opinion of the investigator, would interfere with treatment,
assessment, or compliance with the protocol. This would include renal, cardiac,
hematological, hepatic, pulmonary (including chronic asthma), endocrine (including
diabetes), central nervous, gastrointestinal (including an ulcer), vascular,
metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active
infection, or malignancy that are clinically significant or requiring treatment.
- Presence or history of cardiovascular disease, including structural heart disease,
myocardial infarction (by ECG and/or clinical history), history of ventricular
tachycardia or torsade de pointes, heart failure or cardiomyopathy (by clinical
history and/or left ventricular ejection fraction < 40%), presence of cardiac
conduction abnormalities, a family history of Long QT or Brugada Syndrome, or
unexplained death in an otherwise healthy individual between the ages of 1 and 30
years
- Additional cardiovascular-specific exclusion criteria include findings on screening
ECG of:
- QTcF interval > 430 msec
- PR interval > 220 msec
- QRS duration > 110 msec
- Second- or third-degree atrioventricular block
- Complete left or right bundle branch block or incomplete right bundle branch
block
- Resting heart rate < 40 or > 100 beats per minute (bpm)
- Pathological Q waves (defined as Q wave > 40 msec)
- Ventricular pre-excitation
- More than 2 ectopic beats
- Syncope, palpitations, or unexplained dizziness
We found this trial at
1
site
Click here to add this to my saved trials